Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867815 · ClinicalTrials.gov registry record · Phase 4
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
A Phase 4 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00867815: Clinical Trial Phase 4 study, sponsored by Bayer.
NCT00867815 is a Phase 4 study that was terminated before completion, run by Bayer. The registered enrollment target is 10 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867815, a Phase 4 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
Primary Outcome
The study population consisted of adult men, first diagnosed with NAION which started within 45 days before study start and took PDE5 inhibitors (vardenafil, sildenafil, tadalafil or avanafil) in the 1 year prior to enrollment.
Interventions
- DRUG Diagnostic procedures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-07-13 |
| Est. Completion | 2018-03-28 |
| Phase | Phase 4 |
Why NCT00867815 stopped before completion
NCT00867815 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Diagnostic procedures is the first listed.
NCT00867815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00867815 about?
NCT00867815 is a clinical study titled "PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)". The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
What is the current status of trial NCT00867815?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2009-07-13. Estimated completion is 2018-03-28.
What interventions are being tested in trial NCT00867815?
The interventions under investigation include: Diagnostic procedures (DRUG).
Who is sponsoring clinical trial NCT00867815?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00867815's enrollment target sits among peer trials
10 1940th of 2000 higher than 33 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI